RankAlpha logo
Back to Rankings

XNCR

XencorD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
Primary-source updates support multiple dated pipeline milestones, and management maintained year-end cash guidance and runway into mid-2028 despite the royalty dispute. If XmAb819 data or autoimmune milestones de-risk the pipeline, the current price could be too discounting for a company with several shots on goal.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.6.
What can break
Alexion told Xencor it does not owe additional U.S. Ultomiris royalties and does not intend to make future U.S. payments, creating a live royalty-dispute overhang.
Momentum
90
Value
41
Sentiment
5
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.50 · Bull $16.00 · Bear $8.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $28.33
Why
Momentum90 · Δ7d +0.6
Value41 · Δ7d +0.1
Sentiment5 · Δ7d -17.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
90
26% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+13.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
5
34% active weight
Current posture
7d trendSoftening
Δ7d
-17.0
Δ21d
-15.4
Why this grade

Composite grade D. Momentum 90.1 / Value 41.1 / Sentiment 5.0

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$1.52B
Beta
0.99
Shares Out
74.14M
P/E (TTM) · Derived
-16.5
P/S (TTM)
6.09
P/FCF (TTM) · Derived
-8.09
Rev YoY
-86.2%
EPS YoY
+160.7%
Gross Margin
+89.3%
Op Margin
-76.6%
Net Debt
-$359.99M
Current Ratio
6.57
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology